PREVENTIS
LIVE

Serial Number

79302096

Owner

Immundiagnostik AG

Attorney

Michael T. Smith

Filing Date

Dec 4, 2020

Add to watchlist:

No watchlists yet
View on USPTO

PREVENTIS Trademark

Serial Number: 79302096 • Registration: 6681425

PREVENTIS is a trademark filed by Immundiagnostik AG on December 4, 2020. The trademark is classified under Class 5 (Pharmaceuticals). The application is currently registered and active.

Owner Contact Info

Immundiagnostik AG (30 trademarks)

Bensheim 64625 , DE

Entity Type: 03

Trademark Details

Filing Date

December 4, 2020

Registration Date

March 29, 2022

Published for Opposition

January 11, 2022

Goods & Services

diagnostic and analytical means for medical purposes in particular chemical preparations for use in disease prevention, namely, for detecting and preventing infectious diseases, in particular, infectious diseases caused by viruses, namely, influenza virus, SARS, RSV, infectious diseases caused by bacteria, namely, leptospirosis, Lyme disease, gonorrhea, syphilis, Helicobacter pylori infection, botulism, tetanus, meningitis, pneumonia, endocarditis, Pink eye, erysipelas, necrotizing fasciitis, chlamydia infection, tuberculosis, infectious diseases caused by monocellular organisms, namely, fungi, amoebozoa, entamoebia, dermatophytesm, ringworm, tinea, tinea pedis, oncological diseases, namely, colorectal cancer, cancers of colon, bladder, testicles, prostate, lymphoma, gastroenterological diseases, namely, morbus Crohn, celiac disease, inflammatory bowel syndrome (IBS), inflammatory bowel disease (IBD), diseases and conditions diagnosed by gluten-derived immunogenic peptides (GIP) in stool, urine, diseases of the bones, gastrointestinal diseases increasing the concentration of calprotectin in blood, serum, feces, gastrointestinal syndromes, metabolic diseases, diseases caused by unbalanced vitamin supply and malnutrition, in particular, vitamin D, vitamin B1, vitamin B12, diseases affecting the concentration of the Thyroid-stimulating hormone (TSH), C-reactive protein (CRP), D-Dimer, microalbumin in bodily fluids, urine, and stool, cardiovascular diseases, namely, myocardial infarct, diseases affecting the troponin-level in bodily fluids, conditions affecting women's health, in particular, the concentration of choriogonadotropin, ollicle-stimulating hormone (FSH), luteinizing hormone (LH) in bodily fluids and urine; chemical preparations for use in medical and pharmaceutical detection kits, namely, for detecting infectious diseases, in particular, infectious diseases caused by viruses, namely, influenza virus, SARS, RSV, infectious diseases caused by bacteria, namely, leptospirosis, Lyme disease, gonorrhea, syphilis, Helicobacter pylori infection, botulism, tetanus, meningitis, pneumonia, endocarditis, Pink eye, erysipelas, necrotizing fasciitis, chlamydia infection, tuberculosis, infectious diseases caused by monocellular organisms, namely, fungi, amoebozoa, entamoebia, dermatophytesm, ringworm, tinea, tinea pedis, oncological diseases, namely, colorectal cancer, cancers of colon, bladder, testicles, prostate, lymphoma, gastroenterological diseases, namely, morbus Crohn, celiac disease, inflammatory bowel syndrome (IBS), inflammatory bowel disease (IBD), diseases and conditions diagnosed by gluten-derived immunogenic peptides (GIP) in stool, urine, diseases of the bones, gastrointestinal diseases increasing the concentration of calprotectin in blood, serum, feces, gastrointestinal syndromes, metabolic diseases, diseases caused by unbalanced vitamin supply and malnutrition, in particular, vitamin D, vitamin B1, vitamin B12, diseases affecting the concentration of the Thyroid-stimulating hormone (TSH), C-reactive protein (CRP), D-Dimer, microalbumin in bodily fluids, urine, and stool, cardiovascular diseases, namely, myocardial infarct, diseases affecting the troponin-level in bodily fluids, conditions affecting women's health, in particular, the concentration of choriogonadotropin, ollicle-stimulating hormone (FSH), luteinizing hormone (LH) in bodily fluids and urine; chemicals for medical diagnostics and analysis relating to infectious diseases, in particular, infectious diseases caused by viruses, namely, influenza virus, SARS, RSV, infectious diseases caused by bacteria, namely, leptospirosis, Lyme disease, gonorrhea, syphilis, Helicobacter pylori infection, botulism, tetanus, meningitis, pneumonia, endocarditis, Pink eye, erysipelas, necrotizing fasciitis, chlamydia infection, tuberculosis, infectious diseases caused by monocellular organisms, namely, fungi, amoebozoa, entamoebia, dermatophytesm, ringworm, tinea, tinea pedis, oncological diseases, namely, colorectal cancer, cancers of colon, bladder, testicles, prostate, lymphoma, gastroenterological diseases, namely, morbus Crohn, celiac disease, inflammatory bowel syndrome (IBS), inflammatory bowel disease (IBD), diseases and conditions diagnosed by gluten-derived immunogenic peptides (GIP) in stool, urine, diseases of the bones, gastrointestinal diseases increasing the concentration of calprotectin in blood, serum, feces; gastrointestinal syndromes, metabolic diseases, diseases caused by unbalanced vitamin supply and malnutrition, in particular, vitamin D, vitamin B1, vitamin B12, diseases affecting the concentration of the Thyroid-stimulating hormone (TSH), C-reactive protein (CRP), D-Dimer, microalbumin in bodily fluids, urine, and stool, cardiovascular diseases, namely, myocardial infarct, diseases affecting the troponin-level in bodily fluids, conditions affecting women's health, in particular, the concentration of choriogonadotropin, ollicle-stimulating hormone (FSH), luteinizing hormone (LH) in bodily fluids and urine; all the aforesaid goods not for veterinary use; chemicals for medical diagnostics and analysis in the nature of chemical preparations for rapid testing of infectious diseases caused by viruses, namely, influenza virus, SARS, RSV, infectious diseases caused by bacteria, namely, leptospirosis, Lyme disease, gonorrhea, syphilis, Helicobacter pylori infection, botulism, tetanus, meningitis, pneumonia, endocarditis, Pink eye, erysipelas, necrotizing fasciitis, chlamydia infection, tuberculosis, infectious diseases caused by monocellular organisms, namely, fungi, amoebozoa, entamoebia, dermatophytesm, ringworm, tinea, tinea pedis, oncological diseases, namely, colorectal cancer, cancers of colon, bladder, testicles, prostate, lymphoma, gastroenterological diseases, namely, morbus Crohn, celiac disease, inflammatory bowel syndrome (IBS), inflammatory bowel disease (IBD), diseases and conditions diagnosed by gluten-derived immunogenic peptides (GIP) in stool, urine, diseases of the bones, gastrointestinal diseases increasing the concentration of calprotectin in blood, serum, feces, gastrointestinal syndromes, metabolic diseases, diseases caused by unbalanced vitamin supply and malnutrition, in particular, vitamin D, vitamin B1, vitamin B12, diseases affecting the concentration of the Thyroid-stimulating hormone (TSH), C-reactive protein (CRP), D-Dimer, microalbumin in bodily fluids, urine, and stool, cardiovascular diseases, namely, myocardial infarct, diseases affecting the troponin-level in bodily fluids, conditions affecting women's health, in particular, the concentration of choriogonadotropin, ollicle-stimulating hormone (FSH), luteinizing hormone (LH) in bodily fluids and urine

Filing History

NEW REPRESENTATIVE AT IB RECEIVED
Nov 21, 2025 NREP
INTERNATIONAL REGISTRATION RENEWED
Nov 30, 2023 RNWL
FINAL DECISION TRANSACTION PROCESSED BY IB
Sep 11, 2022 FINO
FINAL DISPOSITION NOTICE SENT TO IB
Aug 19, 2022 FICS
FINAL DISPOSITION PROCESSED
Aug 19, 2022 FIMP
FINAL DISPOSITION NOTICE CREATED, TO BE SENT TO IB
Jun 29, 2022 FICR
REGISTERED-PRINCIPAL REGISTER
Mar 29, 2022 R.PR
OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Jan 11, 2022 NPUB
PUBLISHED FOR OPPOSITION
Jan 11, 2022 PUBO
NOTIFICATION PROCESSED BY IB
Jan 10, 2022 GPNX
NOTIFICATION OF POSSIBLE OPPOSITION SENT TO IB
Dec 22, 2021 OPNS
NOTICE OF START OF OPPOSITION PERIOD CREATED, TO BE SENT TO IB
Dec 22, 2021 OP2R
NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Dec 22, 2021 NONP
APPROVED FOR PUB - PRINCIPAL REGISTER
Dec 9, 2021 CNSA
EXAMINER'S AMENDMENT ENTERED
Dec 9, 2021 XAEC
NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
Dec 9, 2021 GNEN
EXAMINERS AMENDMENT E-MAILED
Dec 9, 2021 GNEA
EXAMINERS AMENDMENT -WRITTEN
Dec 9, 2021 CNEA
TEAS/EMAIL CORRESPONDENCE ENTERED
Nov 22, 2021 TEME
CORRESPONDENCE RECEIVED IN LAW OFFICE
Nov 22, 2021 CRFA
TEAS RESPONSE TO OFFICE ACTION RECEIVED
Nov 22, 2021 TROA
REFUSAL PROCESSED BY IB
Jun 13, 2021 RFNT
NON-FINAL ACTION MAILED - REFUSAL SENT TO IB
May 21, 2021 RFCS
REFUSAL PROCESSED BY MPU
May 21, 2021 RFRR
NON-FINAL ACTION (IB REFUSAL) PREPARED FOR REVIEW
May 20, 2021 RFCR
NON-FINAL ACTION WRITTEN
May 19, 2021 CNRT
ASSIGNED TO EXAMINER
May 14, 2021 DOCK
APPLICATION FILING RECEIPT MAILED
Jan 26, 2021 MAFR
NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Jan 21, 2021 NWOS
LIMITATION FROM ORIGINAL APPLICATION ENTERED
Jan 19, 2021 LIMI
SN ASSIGNED FOR SECT 66A SUBSEQ DESIG FROM IB
Jan 7, 2021 SDRC